Summary
Several studies have focused on the role of the metabolism of acetylcholine and the monoamines in the pathophysiology of AD/SDAT.
Different methods have been tried to activate the cholinergic system in the brain. By giving different forms of precursors the synthesis of ACh has been stimulated. Also by giving enzyme inhibitors, the breakdown of ACh has been inhibited, and by giving receptor agonists cholinergic functioning has been activated. The effect of this treatment has, however, been very marginal
Treatment models in which one tries to substitute monoamines have also been adapted in the care of demented patients. The positive effect of levodopa treatment in parkinsonism is well known and as there is reduced activity of DA in the brains of patients with AD/SDAT, the same treatment has been offered to demented patients. Again, however, the effect of the treatment has been marginal or negative. DA agonists have also been used but the experience with this kind of drug is still very limited and convincing positive effects are as yet not shown.
Investigations have been made in which an attempt has been made to substitute in the 5-HT system. These investigations are of special interest as malabsorption of tryptophan has been suspected in some subgroups of senile dementia. Experience is, however, still limited and no conclusion can be drawn.
From a theoretical point of view it would be of interest to use drugs that down-regulate the activity in the NA system. Biochemical findings indicate an increased speed of turnover in the locus ceruleus. Such investigations have not been made.
Alaproclate is a drug which selectively blocks the reuptake of 5-HT, and in preliminary investigations this drug has given positive results in the treatment of organic symptoms. In brains from patients with AD/SDAT there is an increased activity of MAO-B. Although the increase is not considered to be of biological importance the use of MAO inhibitors would be of interest in the treatment of dementia disorders. Such investigations are as yet not made.
Hydergine, a drug that has long been used in the treatment of organic brain syndromes, has gained new interest as its mode of action is reconsidered. The drug seems not only to influence cerebral blood flow, but also neurotransmitter function in the brain. A stimulating effect on DA and 5-HT functioning, and a blockade of NA activity is reported. This pattern of action is of great interest.
Some neuropeptides, such as somatostatin, ACTH analogues and vasopressin have attracted attention. Experience with these peptides in man is still limited. Although the effect on dementia syndromes does not seem to be dramatic, it is of great interest to further investigate the therapeutic value of these drugs. The nootropic agent piracetam has also created interest in the treatment of organic brain disorders. The drug has not been shown to be of value in severely demented patients, but in mild organic brain syndromes effects have been reported, although the findings are not consistent.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adolfsson, R., Gottfries, C.G., Oreland, L., Wiberg, A., and Winblad, B.: Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci. 27, 1029 (1980).
Adolfsson, R., Gottfries, C.G., Nystrom, L., and Winblad, B.: Prevalence of dementia disorders in institutionalized Swedish old people. Acta Psychiat. Scand. 63, 225 (1981).
Alzheimer, A.: Ueber eine eigenartige Erkrankung der Hirnrinde. Cbl. Nervenheilk Psychiat. 18, 111 (1907). Cited in Torack, R., In Wells, C. (Ed.), Dementia. Philadelphia: F.A. Davis, 1971.
Bergman, I., Brane, G.,’ Gottfries, C.G., Jostell, K.G., Karlsson, I., and Svennerholm, L.: Alaproclate: A pharmacokinetic and biochemical study in patients with dementia of Alzheimer type. Psychopharmacology 80, 279 (1983).
Bondareff, W., Mountjoy, C.Q., and Roth, M.: Selective loss of neurons of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Lancet I, 783 (1981).
Corkin, S.: Aceteylcholine, aging and Alzheimer’s disease. Implications for treatment. Trends NeuroSci. 4, 287 (1981).
Delwaide, P.J., Devoitille, J.M., and Ylieff, M.: Acute effect of drugs upon memory of patients with senile dementia. Acta Psychiat. Belg. 80, 748 (1980).
De Wied, D., Van Wimersma Greidanus, T.B., Bohus, B., Urban, I., and Gispen, W.H.: Vasopressin and memory consolidation. Progr. Brain Res. 45, 181 (1976).
Gottfries, C.G.: Levels of monoamines, monoamine metabolites, and activity in related enzyme systems correlated to normal aging and in patients with dementia of Alzheimer type. In Corsini, G.L., and Gessa, G.I. (Eds.), Apomorphine and Other Dopaminomimetics, Vol. 2, pp. 243–249. New York: Raven, 1981.
Gottfries, C.G.: Dementia. In Hippius, H., and Winokur, G. (Eds.), Psycho-pharmacology 1. Part II: Clinical Psychopharmacology, pp. 271–285. Amsterdam, Excerpta Medica (1983).
Gottfries, C.G., Adolfsson, R., Aquilonius, S.M., Carlsson, A., Eckernas, S.A., Nordberg, A., Oreland, L., Svennerholm, L., Wiberg, A., and Winblad, B.: Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiology of Aging 4: 261–271 (1983).
Lehmann, J., Persson, S., Walinder, J., and Wallin, L.: Tryptophan malabsorption in dementia. Improvement in certain cases after tryptophan therapy as indicated by mental behaviour and blood analysis. A pilot study. Acta Psychiatr. Scand. 64, 123 (1981).
Loew, D.M., Van Deusen, E.B., and Meier-Ruge, W.: Effect on the central nervous system. In Berde, B., and Schild, H.O. (Eds.), Ergot alkaloids and related compounds. Handbook of experimental pharmacology, Vol. 49, pp. 421–531. New York: Springer-Verlag, 1978.
Ogren, S.O., Lindberg, U., and Hall, H.: Effects of Alaproclate on the 5-HT uptake mechanism in vivo: Evidence for regional selectivity. Abstract, 12th CINP Congress, Goteborg, Sweden, 22–26 June 1980.
Reisberg, B., Ferris, S.H., and Gershon, S.: An overview of pharmacologic treatment of cognitive decline in the aged. Am. J. Psychiat. 138, 593 (1981).
Weingartner, H., Gold, P., Ballenger, J.C., Smallberg, S.A., Summers, R., Rubinow, D.R., Post, R.M., and Goodwin, F.K.: Effects of vasopressin on human memory functions. Science 211, 601 (1981).
Winblad, B.: Personal communications (1983).
Wurtman, R.J., Hirsch, M.J., and Growdon, I.H.: Lecithin consumption raises serum-free choline levels. Lancet II, 68 (1977).
Zawadski, R.T., Glazer, G.B., and Lurie, E.: Psychotropic drug use among institutionalized and noninstitutionalized medicaid aged in California. J. Gerontol. 33, 824 (1978).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Springer-Verlag New York Inc.
About this paper
Cite this paper
Gottfries, C.G. (1985). Rationale for the Use of Therapeutic Agents in Affective Disorders (AD) and Senile Dementia of the Alzheimer Type (SDAT). In: Gaitz, C.M., Samorajski, T. (eds) Aging 2000: Our Health Care Destiny. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-5058-6_27
Download citation
DOI: https://doi.org/10.1007/978-1-4612-5058-6_27
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-9544-0
Online ISBN: 978-1-4612-5058-6
eBook Packages: Springer Book Archive